Participants receive education about both cancer and CVD risk factors and their relationship to dietary and physical activity health behaviors.

Participants receive education about CVD risk factors and their relationship to dietary and physical activity health behaviors.

Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.

Integrated vs Non-integrated Risk Education

Chanita H Halbert, PhD

The investigators will evaluate the effects of an integrated risk counseling program on behavioral and psychological outcomes in African American men and women in a randomized trial that is implemented and evaluated collaboratively through the West Philadelphia Consortium to Address Disparities. The specific aims of this research are as follows:

1. To evaluate the effects of integrated versus disease specific counseling on risk exposure behaviors. The investigators predict that compared to individuals who receive disease specific counseling, those who receive integrated counseling will report greater intake of fruits and vegetables and increased rates of physical activity.
2. To evaluate effects of integrated versus disease specific counseling on psychological outcomes. The investigators predict that compared to individuals who receive disease specific counseling, those who receive integrated counseling will report greater risk comprehension related to cancer and cardiovascular disease and will be more motivated to make behavioral changes.
3. To identify the mechanisms through which integrated risk counseling leads to behavioral change. The investigators predict that changes in risk exposure behaviors (e.g., diet and physical activity) will be mediated by increased risk comprehension and self-efficacy for diet and physical activity.

West Philadelphia Consortium Randomized Control Trial

West Philadelphia Consortium to Address Disparities

University of Pennsylvania

Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Nutritional and Metabolic Diseases

Syndrome

Hypertension

Polycystic Ovary Syndrome

Metabolic Syndrome

Insulin Resistance

Hyperinsulinism

Metabolic Diseases

Glucose Metabolism Disorders

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

All Drugs and Chemicals

Vasoconstrictor Agents

Respiratory System Agents

Androgens

Epinephrine

Racepinephrine

Epinephryl borate

Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:

1. Oligo- or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Ming-I Hsu, MD

Polycystic ovary syndrome (PCOS) is an extremely common disorder in women of reproductive age. Diagnosis of PCOS is principally based on clinical and physical findings. Diagnostic criteria and PCOS definitions used by clinicians and researchers are almost as heterogeneous as the syndrome. Of those diagnosed with PCOS using the 2003 Rotterdam criteria, 61% fulfilled 1990 NIH criteria for unexplained hyperandrogenic chronic anovulation. The patient populations with the new phenotypes had less severe ovulatory dysfunction and less androgen excess than patients diagnosed using the 1990 NIH criteria. These findings might be common across all female populations with PCOS, whether in Oriental or Occidental countries. Data for clinical hyperandrogenism indicated that the prevalence of hirsutism in Taiwanese PCOS women is lower than that for Caucasians/Western women.

The extent of metabolic abnormalities in women with PCOS may vary with phenotype, age and ethnicity. Obesity represents a major risk factor for metabolic syndrome and insulin resistance. Approximately 40-50% of all women with PCOS are overweight or obese. Obese subjects with PCOS had a higher risk of developing oligomenorrhea, amenorrhea and biochemical hyperandrogenemia than non-obese women with PCOS. Moreover, obese women with PCOS had significantly more severe insulin resistance, lower serum LH levels, and lower LH-to-FSH ratios than non-obese women with PCOS. PCOS women in Taiwan presented with higher LH-to-FSH ratio and lower insulin resistance than PCOS women in Western Countries. However, the average body mass index (BMI) was significantly lower in Taiwanese PCOS women than Western women, which might partially explain the difference between these two populations in terms of clinical and biochemical presentations.

To further document the ethnic variation between women with PCOS in Taiwan and Western, the effect of obesity on the diagnosis and clinical presentations of PCOS-related syndromes should not be neglected in future studies. Therefore, the investigators plan to do this prospective study for evaluation the clinical and biochemical presentation of Taiwanese women with PCOS.

1. Method

1. This study was approved by the Institutional Review Board of the Wan Fang Medical Center at Taipei Medical University (WF99041, approved August 2010) and performed at the Reproductive Endocrinology Clinic at the Wan Fang Medical Center from 31 August 2010 to 31 August 2011. The following women were excluded: (i) women who had been diagnosed with hyperprolactinemia, hypogonadotropic hypogonadism, premature ovarian failure, congenital adrenal hyperplasia, androgen-secreting tumor,Cushing's syndrome, disorders of the uterus and chromosomal anomalies; (ii) women who were less than three years past menarche or who were older than 45 years; (iii) women who received hormones or medication for major medical diseases (diabetes or cardiovascular disease); and (iv) women who had had ovarian cysts or ovarian tumors identified by ultrasonographic examination.
2. Statistical analysis: We used chi-squared and Fisher's exact tests to perform categorical comparisons and ANOVA to compare the continuous variables. The means of more than two groups were compared using one-way ANOVA and post hoc Dunnett's t-test with equal variances not assumed.

To Study Polycystic Ovary Syndrome in Taiwanese Women

Using serum total testosterone to represent the severity of hyperandrogenism.

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

A fasting serum insulin level of greater than the upper limit of normal for the assay used (approximately 60 pmol/L) is considered evidence of insulin resistance.

Fasting blood sugar (FBS) measures blood glucose after you have not eaten for at least 8 hours. It is often the first test done to check for prediabetes and diabetes.

World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).

2-hour postprandial blood sugar measures blood glucose exactly 2 hours after you start eating a meal. This is not a test used to diagnose diabetes.

World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).

HOMA-IR = \[fasting insulin (in μIU/mL) × fasting glucose (in mg/dL)\]/405.

Hypercholesterolemia was defined as \>6 mmol / L.

Abnormal serum triglycerides defined as ≥ 1.7 mmol/L

Metabolic syndrome was defined (2005 National Cholesterol Education Program, Adult Treatment Panel III) as the presence of at least three of the following criteria:

abdominal obesity (waist circumference \>80 cm in women); serumtriglycerides≥1.7 mmol/L; serumHDL\<1.3 mmol/L; systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg; and fasting plasma glucose ≥7.0 mmol/L.

Lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and sex hormone binding globulin (SHBG).

Abnormal LDL was ≧4.14mmol/L.

Impaired glucose tolerance was defined as two hour glucose levels of 7.8-11.1 mmol/L in the 75 g oral glucose tolerance test. In women with impaired glucose tolerance, the fasting plasma glucose level should be \<7 mmol/L.

Taipei Medical University WanFang Hospital

Attending Doctor

Control

PCOS

Total

Age, Continuous

Sex: Female, Male

Taiwan

Region of Enrollment

Dr. Ming-I Hsu

Total Testosterone

Fasting Insulin

Fasting Glucose

Two Hour Glucose

Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR)

Cholesterol

Triglycerides

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:

1. Oligo- or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Obese With PCOS

Obese With Control

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI \< 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:

1. Oligo- or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Non-obese With PCOS

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI \< 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

Nonb-obese With Control

Impaired Glucose Tolerance

Overall Study

PCOS is the most common endocrine disorder in reproductive women. It is estimated that 5 to 10% of women of reproductive age have PCOS. One of the major diagnostic criteria of PCOS was chronic anovulation which lead to irregular menstruation, amenorrhea, and infertility; the other diagnostic criteria was hyperandrogenism which lead to hirsutism, acne and alopecia. Furthermore, PCOS is thought as a metabolic disorder, the long-term consequence of PCOS were diabetes mellitus and cardiovascular disease, which are potentially dangerous in women health. Early diagnosis and prevention is very important to the PCOS patients.

Obesity is the most potential risk of threat to health of populations. There is a major impact of obesity on the PCOS related disorders. Insulin resistance and distribution of adipose tissue were thought to be the important risk factors of cardiovascular and metabolic syndrome.

To treat PCOS patients properly,Wan-Fang hospital had established a specific medical team. The investigators recently published in "Fertility and Sterility" about the clinical presentation of androgen excess in Taiwanese women. Hirsutism is much less prevalence in Taiwanese PCOS women than that previous reported in the Western women. It is important to know that some clinical presentation of PCOS might have ethic variance. Insulin resistance was reported as another candidate that might have ethic variance.The investigators had reported about 40% women in PCOS women were obese, it is similar with previous literature reported. Obesity is a major factor that could be controlled during the treatment of PCOS.Weight reduction is one of our methods in PCOS treatment. The progressive results for obese PCOS women would be facing the risks of diabetes and metabolic syndrome.The investigators thought like to evaluate the benefit of weight reduction program to the prognosis of obese women with PCOS. Furthermore, it is known that Endothelial progenitor cells (EPC) be an early marker of cardiovascular disease, the investigators would like to know the role of EPC to predict metabolic syndrome in women with PCOS. Wan-Fang hospital has a professional team in PCOS treatment and research which including gynecological endocrinologist, cardiologist, medical endocrinologist, specialist in weight reduction. This team had been working well for more that 4 years.

The investigators hope that they can make a contribution to the study and treatment of PCOS in Taiwan.

Study of Metabolism and Cardiovascular Disease(CVD) in Women With Polycystic Ovary Syndrome (PCOS)

The Risk of Metabolic Syndrome and Cardiovascular Disease in Women With Polycystic Ovary Syndrome.

Diabetes Mellitus, Type 2

Diabetes Mellitus

Obesity

Prediabetic State

Glucose Intolerance

Hypoglycemic Agents

Metformin

randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2

randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.

randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2

DPPOS Group Lifestyle

Administered as 850mg twice per day, masked in DPP and open label in DPPOS

In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.

DPPOS Boost Lifestyle

16 session curriculum in group format. In DPP delivered to ILS as individual sessions

Intensive Lifestyle Group Session

David M. Nathan, MD

Marinella Temprosa, PhD

Barbara Linder, MD, PhD

Kishore Gadde, MD

David Ehrmann, MD

Kevin Furlong, MD

Kathleen Jablonski, PhD

Ronald B Goldberg, MD

Helen P Hazuda, MD

Dana Dabelea, MD, PhD

Medha Munshi, MD

Steven Kahn, MB, ChB

Samuel Dagogo-Jack, MD, MB

Mark Molitch, MD

Happy Araneta, PhD,MPH

F. Xavier Pi-Sunyer, MD

Kieren J Mather, MD

Michelle Magee, MD

Karol E Watson, MD

Angela Brown, MD

Sherita Hill Golden, MD, MHS

David S Schade, MD

Jill Crandall, MD

Elizabeth Venditti, PhD

Marjerie Mau, MD

William Knowler, MD

Santica M Marcovina, PhD

David M Nathan, MD

Christine Lee, MD

Sunder Mudaliar, MD

The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.

DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.

The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.

The current DPPOS Executive Summary and protocol, as well as DPPOS protocol and lifestyle manuals and publications are available at: http://www.dppos.org

Diabetes Prevention Program Outcomes Study

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repository

Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level \>= 126 mg/dL \[7.0 mmol/L\] or 2-hour plasma glucose \>= 200 mg/dL \[11.1 mmol/L\], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test).

Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (\<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (\> 30mg/gm, confirmed).

All primary incident cancers except non-melanoma skin cancer

Defined as MI, stroke and CVD death. These outcomes were collected since randomization and adjudicated by an outcomes committee who are blinded to treatment assignment.

Measured using coronary artery calcification (CAC).

Cognitive function defined as a composite measure constructed from tests of memory (English Spanish Verbal Learning Test) and executive function (word fluency and Digit Symbol Substitution Test ).

Physical function is measured using the short physical performance battery (SPPB), which is comprised of measures of 1) time to walk 3-4 meters, 2) balance, i.e., side-by-side stand, semi-tandem stand, and tandem stand, and 3) repeated chair stands.

Description: The Cardiovascular Health Study Frailty score is based on 5 frailty characteristics: slow walking speed, low energy expenditure, exhaustion, weak grip strength, and unintentional weight loss.

All cause-mortality through clinic reports and National Death Index search

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Aging (NIA)

National Institute on Minority Health and Health Disparities (NIMHD)

National Heart, Lung, and Blood Institute (NHLBI)

National Cancer Institute (NCI)

National Eye Institute (NEI)

National Center for Research Resources (NCRR)

Office of Research on Women's Health (ORWH)

Centers for Disease Control and Prevention

American Diabetes Association

Indian Health Service

General Clinical Research Program

US Department of Veterans Affairs

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Boost / Lifestyle, previously Intensive Lifestyle during the DPP

Group Lifestyle: Quarterly group lifestyle sessions

Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.

1 Original Lifestyle

Metformin / Lifestyle, previously the metformin treatment group during DPP

Group Lifestyle: Quarterly group lifestyle sessions

Metformin: Administered as 850mg twice per day

2 Original Metformin

Group Lifestyle, previously placebo treated participants during DPP

Group Lifestyle: Quarterly group lifestyle sessions

3 Original Placebo

randomized to unmasked Intensive Lifestyle (ILS) during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2

DPPOS Group Lifestyle: Quarterly group lifestyle sessions

DPPOS Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.

Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions

randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.

DPPOS Group Lifestyle: Quarterly group lifestyle sessions

Metformin: Administered as 850mg twice per day, masked in DPP and open label in DPPOS

Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions

randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2

DPPOS Group Lifestyle: Quarterly group lifestyle sessions

Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions

An additional 3 participants were enrolled after publication

Race (NIH/OMB)

United States

Marinella Temprosa, PI of Coordinating Center

Development of Diabetes.

Number with microvascular outcome data and included in the primary outcome analysis

Prevalence of Aggregate Microvascular Complication

Total Cancer Except Non-melanoma Skin Cancer

Major Adverse Cardiovascular Events (MACE): Myocardial Infarction (MI), Stroke, or Cardiovascular Death (CVD)

Women

randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2

DPPOS Group Lifestyle: Quarterly group lifestyle sessions

DPPOS Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.

Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions

DPPOS Participants who met eligibility criteria and consented to have CAC measurements - by sex

Subclinical Atherosclerosis

Cognitive Function

Short Physical Performance Battery

Frailty

Mortality

Prostatic Neoplasms

Plaque, Atherosclerotic

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases, Male

Prostatic Diseases

Male Urogenital Diseases

Pathological Conditions, Anatomical

Biopsy-proven prostate cancer patients who have abdomen CT studies that were available in the clinical PACS (picture archiving system) in the Clinical Center.

Men or women of all age and race, who have Multiphase abdomen-pelvic CT studies that were available in the PACS.

Ronald M Summers, M.D.

Background:

Fat and calcium can build up as plaque in artery walls. The Agatston score measures plaque using computed tomography (CT) that does not use an injected contrast agent. Plaque in the arteries of the pelvis and abdomen is linked to cardiovascular disease (CVD) risk factors. It also may affect cancer. But abdominal CTs use a contrast agent (CECT). Therefore, the Agatston score cannot be used. Researchers want to find a way to measure plaque in CECTs. This will help them use abdominal CTs to measure plaque without extra radiation.

Objective:

To measure atherosclerotic plaques on CECT in a group of males.

Eligibility:

Men ages 30-90 with prostate cancer (proven with biopsies) who have abdomen CT studies in the PACS (picture archiving system) in the Clinical Center. Also, men or women of all ages who have multiphase abdomen and pelvic CT studies that are in the PACS.

Design:

This study will use data gathered since 1/1/2013. Data will also be taken from protocol 03-CC-0128 and clinical trials 15-C-0124, 16-C-0048, 14-C-0112, and 04-C-0274. Participants from these studies have allowed their samples to be used in the future.

Participants will be found via keyword searches on NIH databases. Their CT and MRI scans will be used. Data such as age, race, disease, and treatment will be used. Results of other tests may be used.

The plaque in participants abdomen and iliac arteries will be measured. It will be compared with biomarkers related to CVD and prostate cancer, such as weight, age, and race.

This study will take place at one site. Data will be stored on secure computers. Printouts will be kept in locked rooms.

Evaluation of Atherosclerotic Plaques in Prostate Cancer Patients.

Study Description:

This study measures atherosclerotic plaques in the vessels of prostate cancer patients in contrast-enhanced computed tomography (CECT), then finds correlation between the plaque and clinical biomarkers. These biomarkers include laboratory tests, pathologic findings, underlying risk factors, demographic information, and outcomes of the patient.

Objectives:

Primary objective: Measure atherosclerotic plaques on contrast-enhanced computed tomography (CECT).

Secondary objective: Find correlation between plaque measurement and clinical biomarkers of prostate cancer patients.

Study Population:

Up to 1,000 NIH Clinical Center patients.

Description of Sites/Facilities conducting research:

NIH Clinical Center

Study Duration:

10 years

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
West Philadelphia Consortium Randomized Control Trial	NCT01299883	Cancer Cardiovascular ...	Integrated vs N...	18 Years - 75 Years	University of Pennsylvania
To Study Polycystic Ovary Syndrome in Taiwanese Women	NCT01256944	Polycystic Ovar... Metabolic Syndr... Cardiovascular ...		15 Years - 45 Years	Taipei Medical University WanFang Hospital
Study of Metabolism and Cardiovascular Disease(CVD) in Women With Polycystic Ovary Syndrome (PCOS)	NCT01117558	Polycystic Ovar...		15 Years - 45 Years	Taipei Medical University WanFang Hospital
West Philadelphia Consortium Randomized Control Trial	NCT01299883	Cancer Cardiovascular ...	Integrated vs N...	18 Years - 75 Years	University of Pennsylvania
To Study Polycystic Ovary Syndrome in Taiwanese Women	NCT01256944	Polycystic Ovar... Metabolic Syndr... Cardiovascular ...		15 Years - 45 Years	Taipei Medical University WanFang Hospital
Diabetes Prevention Program Outcomes Study	NCT00038727	Diabetes Mellit... Cancer CVD	DPPOS Group Lif... Metformin DPPOS Boost Lif... Intensive Lifes...	25 Years -	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies	NCT04652973	Prostatic Neopl...		30 Years - 90 Years	National Institutes of Health Clinical Center (CC)
Study of Metabolism and Cardiovascular Disease(CVD) in Women With Polycystic Ovary Syndrome (PCOS)	NCT01117558	Polycystic Ovar...		15 Years - 45 Years	Taipei Medical University WanFang Hospital

Spots Global Cancer Trial Database for cvd

Every month we try and update this database with for cvd cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for cvd

Every month we try and update this database with for cvd cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for cvd cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.